• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Paxil (paroxetine hydrochloride)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Paxil (paroxetine hydrochloride)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Paxil has been approved for the treatment of panic disorder, a disabling condition that will affect three to six million Americans at some time in their lives. Paxil belongs to a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs).

    For many years, the only drug indicated for panic disorder was the benzodiazepine tranquilizer alprazolam. However, alprazolam is associated with dependence and is not indicated for long-term treatment of this chronic condition. Paxil has not been associated with the development of dependence in clinical trials and is indicated for long-term treatment of panic disorder.

    In addition, alprazolam is not indicated for major depression, and as many as 65% of patients with panic disorder may also suffer from depression. Paxil is indicated for the treatment of depression as well as panic disorder.

    For the treatment of panic disorder, the recommended target dose of Paxil is 40 mg per day. The starting dose is 10 mg per day, and dosage should not exceed 60 mg per day. Paxil is available in 10, 20, 30, and 40 mg tablets.

    Paxil has also been approved as treatment for obsessive-compulsive disorder. Obsessions are recurrent and persistent thoughts that are intrusive and inappropriate, as well as distressing or anxiety-provoking. Compulsions are repetitive behaviors such as hand-washing or mental acts such as repeating words silently, and are aimed at reducing the distress or preventing some dreaded event.

    The recommended dosage of Paxil in the treatment of obsessive-compulsive disorder is 40 mg daily. The starting dose is 20 mg per day, and dosage should not exceed 60 mg per day.

    Clinical Results

    In one 10-week double-blind clinical study, 76% of subjects treated with 40 mg per day of Paxil were completely free of full panic attacks at the end point, compared with 44% of subjects who received placebo. Patients who responded to Paxil during the initial 10-week phase and a three-month double-blind extension phase were randomly assigned to continue on Paxil or be switched to placebo for an additional three months. Of the subjects switched to placebo, 30% experienced a relapse, as compared with only 5% of those who were treated with Paxil.

    Paxil is the only SSRI that has demonstrated long-term maintenance of efficacy in a six-month relapse-prevention clinical trial. This is important because OCD is a chronic condition and often requires long-term treatment.

    Side Effects

    Paxil was well tolerated in clinical trials for panic disorder and OCD. Side effects with an incidence of 10% or greater and at least twice that of placebo were sleepiness, nausea, abnormal ejaculation, dry mouth, constipation, dizziness, and tremor.

    Additional Information

    Panic disorder is characterized by recurrent panic attacks. A panic attack is a sudden, unprovoked episode in which sufferers experience physical symptoms such as racing, pounding heartbeat, chest pain, breathlessness, and choking and may fear they are losing control or are in imminent danger of dying. Panic disorder is diagnosed when a person has:

    • persistent anxiety about having another attack
    • concern over the implications of the attacks or their consequences, including fear of life-threatening illness or "losing control"
    • behavioral changes due to the attacks, including avoidance of everyday activities

    Women are twice as likely as men to suffer from panic disorder, and the most common age of onset is the late teens and early twenties. Yet, panic attacks and panic disorder are found in people of all ages. Despite its prevalence, panic disorder is under diagnosed, according to the National Institute of Mental Health, which estimates that only one out of three panic disorder sufferers has been correctly diagnosed and treated.

    Approval Date: 1996-05-01
    Company Name: SmithKline Beecham
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Virtual Doctoer

      Simple Changes Can Make Trials More Patient Friendly

    • Drug approval

      Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

    • VaccinewithNeedle-360x240.png

      Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

    • AskTheExperts-360x240.png

      Ask the Experts: Trial Operations Adjustments in a Remote World

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing